Something that seldom gets talked about is that if Zenith Epigenetics or some part thereof gets bought up, that does not get your shares bought and cash in your pocket. You don't own ZENE, it is a wholly owned subsidiary of ZCC and that is who would receive the cash. Then it is up to the Board to decide if they are going to dividend some or all of it out to us. If they didn't sell all of the IP in the deal, they would want to keep some of the cash to R & D those molecules. Almost a year ago, DM hinted to someone that a deal might be in the works with money for Zenith shareholders but it has never happened. If it will or would have happened, we have no idea of what proprtion might come to us and how. Some people would feel differently toward dividends or capital gains but it appears at this point that it would be dividends. To make it capital gains, ZCC would have to be sold or at least listed so the value could show in the shares and realized in a sale there. What value would a tradable share have that has just cash (lots of it) and royalty preferred shares in RVX. The value is limited as there is no room for growth if the IP is all gone. It would be interesting to hear management's explanation of how this would transpire.